An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 14 Feb 2018 Planned End Date changed from 23 Jun 2019 to 26 Jul 2019.
- 14 Feb 2018 Planned primary completion date changed from 19 Mar 2019 to 26 Jul 2019.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.